[
 {
  "pmid": "36190832",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Proteome-wide MR of plasma proteins instrumented by pQTLs on hypothyroidism, a disease, with directions stated in the results.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 398,
   "end": 525
  },
  "claim": {
   "protein_as_written": "interferon [IFN]-lambda-1",
   "gene": "IFNL1",
   "disease_as_written": "hypothyroidism",
   "direction": "raises",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 928,
    "end": 1373
   }
  },
  "flags": {
   "reports_colocalisation": true,
   "coloc_criterion": "PP.H4",
   "coloc_value": 0.998,
   "colocalisation_quote": {
    "in": "abstract",
    "start": 1579,
    "end": 1736
   },
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "36194249",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Two-sample MR of plasma protein levels (ARIC) on type 2 diabetes, a disease, with a stated protein-disease pair.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1512,
   "end": 1775
  },
  "claim": {
   "protein_as_written": "complement C2",
   "gene": "C2",
   "disease_as_written": "type 2 diabetes",
   "direction": "raises",
   "estimate": {
    "or": 1.65,
    "low": null,
    "high": null,
    "unit": "per standard deviation",
    "frame": "per higher protein"
   },
   "significance": "nominal",
   "quote": {
    "in": "abstract",
    "start": 1512,
    "end": 1775
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "36520639",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Besides biomarker-weighted drug targets, the paper instruments circulating apolipoprotein B level with GWAS variants and tests it on heart failure; that pair is stated without a direction, so the claim is unsigned.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 436,
   "end": 859
  },
  "claim": {
   "protein_as_written": "ApoB",
   "gene": "APOB",
   "disease_as_written": "HF",
   "direction": "unstated",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 860,
    "end": 1032
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "36579647",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "MR of plasma protein levels (per SD) on abdominal aortic aneurysm; conclusions give low neogenin as a risk factor.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1571,
   "end": 1764
  },
  "claim": {
   "protein_as_written": "neogenin",
   "gene": "NEO1",
   "disease_as_written": "AAA",
   "direction": "lowers",
   "estimate": {
    "or": 0.5,
    "low": null,
    "high": null,
    "unit": "per standard deviation",
    "frame": "per higher protein"
   },
   "significance": "nominal",
   "quote": {
    "in": "abstract",
    "start": 1778,
    "end": 1893
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "36637422",
  "eligibility": "E2",
  "e2_kind": "no protein exposure",
  "eligibility_reason": "The exposures are blood metabolites, not proteins.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 752,
   "end": 852
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "36694207",
  "eligibility": "E2",
  "e2_kind": "no protein exposure",
  "eligibility_reason": "Exposures are blood metabolites (HDL-C, acetate), not proteins.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 421,
   "end": 582
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "36805566",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "MR of plasma protein levels (per s.d.) on critically ill COVID-19, an infection outcome; NPNT raises its odds.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 441,
   "end": 562
  },
  "claim": {
   "protein_as_written": "nephronectin (NPNT)",
   "gene": "NPNT",
   "disease_as_written": "critically ill COVID-19",
   "direction": "raises",
   "estimate": {
    "or": 1.71,
    "low": null,
    "high": null,
    "unit": "per standard deviation",
    "frame": "per higher protein"
   },
   "significance": "nominal",
   "quote": {
    "in": "abstract",
    "start": 677,
    "end": 823
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "36821647",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Cis-MR of plasma proteins on sarcopenia, a diagnosed condition; conclusions name TNF12 and HGF without direction, results give HGF a negative association.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 211,
   "end": 353
  },
  "claim": {
   "protein_as_written": "HGF",
   "gene": "HGF",
   "disease_as_written": "sarcopenia",
   "direction": "lowers",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1077,
    "end": 1299
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 1660,
    "end": 1791
   }
  }
 },
 {
  "pmid": "36824751",
  "eligibility": "E4",
  "e2_kind": null,
  "eligibility_reason": "Plasma pQTL MR is reported only as unnamed proteins affecting traits and diseases; the abstract names no protein-disease pair.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 573,
   "end": 810
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "36857861",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Proteome-wide MR of circulating protein levels (deCODE) on IBD; conclusions name proteins without direction, results give MST1 an inverse association.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 405,
   "end": 560
  },
  "claim": {
   "protein_as_written": "MST1",
   "gene": "MST1",
   "disease_as_written": "IBD",
   "direction": "lowers",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1164,
    "end": 1362
   }
  },
  "flags": {
   "reports_colocalisation": true,
   "coloc_criterion": "not stated",
   "coloc_value": null,
   "colocalisation_quote": {
    "in": "abstract",
    "start": 1164,
    "end": 1362
   },
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 1707,
    "end": 1815
   }
  }
 },
 {
  "pmid": "36864689",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "MR of plasma protein levels on multiple sclerosis; conclusions name circulating FCRL3 first without direction, and the results state it is protective.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1525,
   "end": 1616
  },
  "claim": {
   "protein_as_written": "FCRL3",
   "gene": "FCRL3",
   "disease_as_written": "multiple sclerosis",
   "direction": "lowers",
   "estimate": {
    "or": 0.83,
    "low": 0.79,
    "high": 0.89,
    "unit": "per standard deviation",
    "frame": "per higher protein"
   },
   "significance": "corrected",
   "quote": {
    "in": "abstract",
    "start": 1525,
    "end": 1616
   }
  },
  "flags": {
   "reports_colocalisation": true,
   "coloc_criterion": "PP.H4",
   "coloc_value": 0.889,
   "colocalisation_quote": {
    "in": "abstract",
    "start": 2011,
    "end": 2328
   },
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 2660,
    "end": 2832
   }
  }
 },
 {
  "pmid": "37002989",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "Drug targets proxied by variants in their genes weighted by lipid traits from GLGC, plus eQTLs; no circulating-protein instruments.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 538,
   "end": 738
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37034659",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Mediation MR uses genetically proxied circulating CXCL10 levels on CAD, LAAS, and PAD; no sign is stated for CXCL10's own effect, so the claim is unsigned.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1720,
   "end": 1977
  },
  "claim": {
   "protein_as_written": "CXCL10",
   "gene": "CXCL10",
   "disease_as_written": "CAD",
   "direction": "unstated",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1720,
    "end": 1977
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 2481,
    "end": 2705
   }
  }
 },
 {
  "pmid": "37068323",
  "eligibility": "E3",
  "e2_kind": null,
  "eligibility_reason": "Circulating adhesion molecules with cis instruments meet E2, but the outcome is functional outcome (mRS) after ischemic stroke, a severity measure, not a disease.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 784,
   "end": 845
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37337418",
  "eligibility": "E2",
  "e2_kind": "no protein exposure",
  "eligibility_reason": "A methods paper whose empirical application names no protein whose effect on a disease it estimates (only cholesterol-lowering drug targets in general).",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1350,
   "end": 1486
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37399599",
  "eligibility": "E2",
  "e2_kind": "expression or other molecular QTLs",
  "eligibility_reason": "Drug-gene pairs come from genetically predicted gene expression mapped to drug targets (calcium channel blockers); no circulating protein level is the exposure.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 468,
   "end": 690
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37421961",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "Metformin targets are proxied by variants weighted by HbA1c lowering (and expression), not by circulating protein levels.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 634,
   "end": 845
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37511084",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Analyses pool eQTL SMR and pQTL MR, and the claim is stated for 'Apoa2 protein or mRNA' without tying it to the circulating protein's analysis.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1095,
   "end": 1203
  },
  "claim": {
   "protein_as_written": "Apoa2",
   "gene": "APOA2",
   "disease_as_written": "sepsis",
   "direction": "lowers",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1254,
    "end": 1384
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 1562,
    "end": 1630
   }
  },
  "e2_resolved_by": "full text"
 },
 {
  "pmid": "37547327",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "Drug target genes are proxied by variants weighted by LDL-C, not by circulating protein levels.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 821,
   "end": 1076
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37550624",
  "eligibility": "E4",
  "e2_kind": null,
  "eligibility_reason": "pQTL GWAS with MR across 19 phenotypes; the abstract names no specific protein-disease pair, only proteins associated with cardiometabolic traits.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1289,
   "end": 1447
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37563310",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "MR of plasma inflammatory protein pQTLs on immune-mediated diseases; CD40-rheumatoid arthritis is the first MR pair, stated without a direction, so the claim is unsigned.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 215,
   "end": 439
  },
  "claim": {
   "protein_as_written": "CD40",
   "gene": "CD40",
   "disease_as_written": "rheumatoid arthritis",
   "direction": "unstated",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 649,
    "end": 966
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": false,
   "drug_target_quote": null
  }
 },
 {
  "pmid": "37596566",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "Lipid-lowering drug targets proxied by gene variants weighted by lipid traits; claims are for HMGCR inhibition and LPL enhancement.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1037,
   "end": 1267
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37603265",
  "eligibility": "E2",
  "e2_kind": "no protein exposure",
  "eligibility_reason": "Exposures are blood pressure and antihypertensive drug classes, not a named circulating protein's level.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 781,
   "end": 932
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37676424",
  "eligibility": "E3",
  "e2_kind": null,
  "eligibility_reason": "Protein MR with cis-pQTLs has BMI (a quantitative trait) as outcome; other direction is adiposity to protein.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 1555,
   "end": 1799
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37712257",
  "eligibility": "E3",
  "e2_kind": null,
  "eligibility_reason": "MR of plasma ANGPTL3 levels was run on hepatic fat, LDL-C, and triglycerides, which are measures, not diseases.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 2020,
   "end": 2326
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37774922",
  "eligibility": "E3",
  "e2_kind": null,
  "eligibility_reason": "Proteome-wide MR of plasma biomarkers on eGFR, a quantitative trait, not a disease.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 916,
   "end": 1046
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37810867",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "IL6R variants proxy IL-6 signalling downregulation via C-reactive protein reduction, a downstream biomarker.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 722,
   "end": 847
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "37904165",
  "eligibility": "E2",
  "e2_kind": "biomarker-weighted",
  "eligibility_reason": "Drug-target MR of genetic PCSK9 'inhibition' drawing on the Global Lipid Genetics Consortium; the abstract names no biomarker that weights the instruments, so whether they are pQTLs or biomarker-weighted is left to the full text, and coronary artery disease is a positive-control outcome with the expected effect.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 553,
   "end": 834
  },
  "claim": {
   "protein_as_written": "PCSK9",
   "gene": "PCSK9",
   "disease_as_written": "coronary artery disease",
   "direction": "unstated",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1140,
    "end": 1418
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 136,
    "end": 403
   }
  },
  "e2_resolved_by": "full text"
 },
 {
  "pmid": "38030643",
  "eligibility": "E2",
  "e2_kind": "no protein exposure",
  "eligibility_reason": "MR runs from BMI to proteins; no protein is an exposure.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 994,
   "end": 1171
  },
  "claim": null,
  "flags": null
 },
 {
  "pmid": "38049831",
  "eligibility": "eligible",
  "e2_kind": null,
  "eligibility_reason": "Proteome-wide MR of circulating protein levels on CAD; no counting pair is given a direction, so the first named protein (PTK7) is an unsigned claim.",
  "eligibility_quote": {
   "in": "abstract",
   "start": 451,
   "end": 660
  },
  "claim": {
   "protein_as_written": "PTK7",
   "gene": "PTK7",
   "disease_as_written": "CAD",
   "direction": "unstated",
   "estimate": null,
   "significance": "not stated",
   "quote": {
    "in": "abstract",
    "start": 1165,
    "end": 1394
   }
  },
  "flags": {
   "reports_colocalisation": false,
   "coloc_criterion": null,
   "coloc_value": null,
   "colocalisation_quote": null,
   "reports_replication": false,
   "replication_quote": null,
   "drug_target_framing": true,
   "drug_target_quote": {
    "in": "abstract",
    "start": 1165,
    "end": 1394
   }
  }
 }
]
